Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, talks on exciting trials investigating the treatment of melanoma. The LAG-3 antibody has recently been approved by the FDA and could replace the use of single agent PD1 blockade for treating metastatic melanoma. The trial (NCT02519322) investigating neoadjuvant and adjuvant nivolumab with anti-LAG3 antibody relatlimab for patients with resectable clinical stage III melanoma is currently showing favorable results. Upcoming solid CAR-T trials are including melanoma patients and the results of Phase II trial assessing neoantigen vaccine approaches with a PD1 blockade will be released in the near future. This interview took place at the EADO 2022 congress.

свернуть